In recent years, results obtained from different studies with large cohorts have revealed a bond between the presence of extensive lymphocytic infiltration and favourable prognostic associations in the early-stage of breast cancer (BC) and high response rates to neoadjuvant chemotherapy. Examiners used tumors from large cohorts of patients who took part in randomized neoadjuvant and adjuvant clinical trials. The importance of tumor infiltrating lymphocytes (TILs) appears to be subtype-specific and varies depending on the histological characteristics of the tumor. TILs have proven to be a good prognostic marker, but only in highly proliferative breast tumors such as triple negative breast tumors (TNBC) or HER 2 positive BC.In the era when standard, well-known, prognostic and predictive biomarkers are ever changing and the use of molecular profiling analyses are increasing, we are looking for techniques to improve our understanding of tumor biology and improve patient outcome. The relevance of TILs cannot be ignored but needs to be properly evaluated in larger prospective studies which must encompass the parameters set out in previous studies. The use of TILs as prognostic biomarkers in early breast cancer may represent a new dawn, and use of immunotherapy, especially immune checkpoint inhibitors, probably is the future for the breast cancer but it is not yet ready for prime time.
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
2
Liu Jinyu, Zhang Mengyang, Zhao Xin, Ge Shasha, Li Shuang, Peng Lin, Mu Yuxue, Chen Chen, Li Xiaoya, Zhang Rui, Feng Xuanye, Deng Bo, Jia Liqun, Lin Yulin, Wang Yueqi, Cheng Zhiqiang, TaeHoo Yi, Cai Dayong
(2018)
A model for anticancer surveillance was pharmacologically developed to evaluate vitality principle in breast cancer rats
Journal of Traditional Chinese Medicine, 38(6)
10.1016/S0254-6272(18)30981-6
K. S. Titov, S. V. Chulkova, H. M. Zapirov, Z. V. Lorie, M. V. Kiselevskiy
(2024)
Impact of the tumor microenvironment of breast cancer on prognosis and treatment
Russian Journal of Biotherapy, 23(3)
10.17650/1726-9784-2024-23-3-10-17The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.